Advanced Research in Secondary Immunodeficiency in Oncohematological Diseases
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Immunology and Immunotherapy".
Deadline for manuscript submissions: 31 October 2025 | Viewed by 1114
Special Issue Editors
Interests: immunodeficiency; autoimmunity; neuro-endocrino-immunology; pharmacogenomics; soluble molecules; immune-mediated diseases; allergies; vaccines
Special Issues, Collections and Topics in MDPI journals
Interests: inflammatory mediators; the citokine network (interleukins, chemokines, adhesion molecules, lipoxines); the oxidative stress in various areas of clinical immunology; allergy; oncology
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
A diverse range of illnesses known as secondary immunodeficiencies arise when the immune system is weakened by external causes. Recurrent infection is a common symptom of secondary immunodeficiency in people with hematological malignancies. Both the innate immunological deficiencies brought on by the cancer and the side effects of cancer treatments, many of which involve B-cell-depleting effects, contribute to secondary immunodeficiency. The early assessment of immune function in at-risk patient populations and the possibility of secondary immunodeficiency development are essential for creating a timely plan to prevent recurrent infections, which can be fatal or have a major negative impact on patients' quality of life and the continuation of cancer treatment regimens. A functional evaluation of the immune response to immunization is advised for these patients in order to bolster the diagnosis of secondary immunodeficiency. There are still many unanswered questions regarding the pathophysiology of secondary immunodeficiency, including the impact of various cellular and molecular mediators on the development of secondary immunodeficiency, as well as the combination of oxidative stress and non-coding genomic material. Additionally, distinct novel treatments for lymphoproliferative neoplasms, including bcl-2 inhibitors, bispecific antibodies, conjugated antibodies, and CAR-T cells, have the capacity to cause secondary immunodeficiency. In the same vein, more research is required to determine the optimal preventive and therapeutic measures, as well as how transplant therapy affects the capacity to cause immunodeficiency.
Prof. Dr. Giuseppe Murdaca
Prof. Dr. Sebastiano Gangemi
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- secondary immunodeficiencies and opportunistic infections
- secondary immunodeficiencies and B-lymphocytes
- secondary immunodeficiencies and hematological diseases
- secondary immunodeficiencies and cancers
- secondary immunodeficiencies and novel cancer treatments
- secondary immunodeficiencies and oxidative stress
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
